Jahir M. Gutierrez

Jahir M. Gutierrez

Auto-generated profile, based on publicly available information

Jahir M. Gutierrez

Layer 6 AI, Toronto, Canada

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 August 2022 in bioRxiv
Verified
Preprint
Open access
PDF file
SBSharrol Bachas
Sharrol Bachas
GRGoran Rakocevic
Goran Rakocevic
DSDavid Spencer
David Spencer
ASAnand V. Sastry
Anand V. Sastry
RHRobel Haile
Robel Haile
RSRoberto Spreafico
Roberto Spreafico
Traditional antibody optimization approaches involve screening a small subset of the available sequence space, often resulting in drug candidates with suboptimal binding affinity, developability or immunogenicity. Based on two distinct antibodies, we demonstrate that deep contextual language models trained on high-throughput affinity data can quantitatively predict binding of unseen antibody sequence variants. These variants span a K D range of three orders of magnitude over a large mutational space. Our models reveal strong epistatic effects, which highlight the need for intelligent screening approaches. In addition, we introduce the modeling of “naturalness”, a metric that scores antibody variants for similarity to natural immunoglobulins. We show that naturalness is associated with measures of drug developability and immunogenicity, and that it can be optimized alongside binding affinity using a genetic algorithm. This approach promises to accelerate and improve antibody engineering, and may increase the success rate in developing novel antibody and related drug candidates.

27 August 2021 in ESMO Open
Verified
Journal Article
Open access
PJPrantesh Jain
Prantesh Jain
JBJ. Gutierrez Bugarin
J. Gutierrez Bugarin
Avirup GuhaAvirup Guha
Avirup Guha
CJC. Jain
C. Jain
NPN. Patil
N. Patil
ADA. Dowlati
A. Dowlati
Immune checkpoint inhibitors (ICIs) can cause life-threatening cardiovascular adverse events (CVAEs) that may not be attributed to therapy. The outcomes of clinical trials may underestimate treatment-related adverse events due to restrictive eligibility, limited sample size, and failure to anticipate selected toxicities. We evaluated the incidence and clinical determinants of CVAEs in real-world population on ICI therapy. Among 2 687 301 patients diagnosed with cancer from 2011 to 2018, 16 574 received ICIs for any cancer. Patients in the ICI and non-ICI cohorts were matched in a 1 : 1 ratio according to age, sex, National Cancer Institute comorbidity score, and primary cancer. The non-ICI cohort was stratified into patients who received chemotherapy (N = 2875) or targeted agents (N = 4611). All CVAEs, non-cardiac immune-related adverse events occurring after treatment initiation, baseline comorbidities, and treatment details were identified and analyzed using diagnosis and billing codes. Median age was 61 and 65 years in the ICI and non-ICI cohorts, respectively (P < 0.001). ICI patients were predominantly male (P < 0.001). Lung cancer (43.1%), melanoma (30.4%), and renal cell carcinoma (9.9%) were the most common cancer types. CVAE diagnoses in our dataset by incidence proportion (ICI cohort) were stroke (4.6%), heart failure (3.5%), atrial fibrillation (2.1%), conduction disorders (1.5%), myocardial infarction (0.9%), myocarditis (0.05%), vasculitis (0.05%), and pericarditis (0.2%). Anti-cytotoxic T-lymphocyte-associated protein 4 increased the risk of heart failure [versus anti-programmed cell death protein 1; hazard ratio (HR), 1.9; 95% confidence interval (CI) 1.27-2.84] and stroke (HR, 1.7; 95% CI 1.3-2.22). Pneumonitis was associated with heart failure (HR, 2.61; 95% CI 1.23-5.52) and encephalitis with conduction disorders (HR, 4.35; 95% CI 1.6-11.87) in patients on ICIs. Advanced age, primary cancer, nephritis, and anti-cytotoxic T-lymphocyte-associated protein 4 therapy were commonly associated with CVAEs in the adjusted Cox proportional hazards model. Our findings underscore the importance of risk stratification and cardiovascular monitoring for patients on ICI therapy.

1 January 2021 in Journal of Biological Chemistry
Verified
Journal Article
Open access
JGJeffry Granados
Jeffry Granados
ARAnne Richelle
Anne Richelle
JGJahir M. Gutierrez
Jahir M. Gutierrez
PZPatrick Zhang
Patrick Zhang
XZXinlian Zhang
Xinlian Zhang
SNSanjay K. Nigám
Sanjay K. Nigám
How organs sense circulating metabolites is a key question. Here, we show that the multi-specific organic anion transporters of drugs, OAT1 (SLC22A6 or NKT) and OAT3 (SLC22A8), play a role in organ sensing. Metabolomics analyses of the serum of Oat1 and Oat3 knockout mice revealed changes in tryptophan derivatives involved in metabolism and signaling. Direct interaction with the transporters was supported with cell-based transport assays. To assess the impact of the loss of OAT1 or OAT3 function on the kidney, an organ where these uptake transporters are highly expressed, knockout transcriptomic data were mapped onto a "metabolic task"-based computational model that evaluates over 150 cellular functions. Despite the changes of tryptophan metabolites in both knockouts, only in the Oat1 knockout were multiple tryptophan-related cellular functions increased. Thus, deprived of the ability to take up kynurenine, kynurenate, anthranilate, and N-formylanthranilate through OAT1, the kidney responds by activating its own tryptophan-related biosynthetic pathways. The results support the Remote Sensing and Signaling Theory, which describes how "drug" transporters help optimize levels of metabolites and signaling molecules by facilitating organ crosstalk. Since OAT1 and OAT3 are inhibited by many drugs, the data implies potential for drug-metabolite interactions (DMI). Indeed, treatment of humans with probenecid, an OAT-inhibitor used to treat gout, elevated circulating tryptophan metabolites. Furthermore, given that regulatory agencies have recommended drugs be tested for OAT1 and OAT3 binding or transport, it follows these metabolites can be used as endogenous biomarkers to determine if drug candidates interact with OAT1 and/or OAT3.

8 June 2020 in bioRxiv
Verified
Preprint
Open access
PDF file
SISandra Isabel
Sandra Isabel
LGLucía Graña-Miraglia
Lucía Graña-Miraglia
JGJahir M. Gutierrez
Jahir M. Gutierrez
CBCedoljub Bundalovic-Torma
Cedoljub Bundalovic-Torma
HGHelen E. Groves
Helen E. Groves
SPSusan M. Poutanen
Susan M. Poutanen
The COVID-19 pandemic, caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), was declared on March 11, 2020 by the World Health Organization. As of the 31 st of May, 2020, there have been more than 6 million COVID-19 cases diagnosed worldwide and over 370,000 deaths, according to Johns Hopkins. Thousands of SARS-CoV-2 strains have been sequenced to date, providing a valuable opportunity to investigate the evolution of the virus on a global scale. We performed a phylogenetic analysis of over 1,225 SARS-CoV-2 genomes spanning from late December 2019 to mid-March 2020. We identified a missense mutation, D614G, in the spike protein of SARS-CoV-2, which has emerged as a predominant clade in Europe (954 of 1,449 (66%) sequences) and is spreading worldwide (1,237 of 2,795 (44%) sequences). Molecular dating analysis estimated the emergence of this clade around mid-to-late January (10 - 25 January) 2020. We also applied structural bioinformatics to assess D614G potential impact on the virulence and epidemiology of SARS-CoV-2. In silico analyses on the spike protein structure suggests that the mutation is most likely neutral to protein function as it relates to its interaction with the human ACE2 receptor. The lack of clinical metadata available prevented our investigation of association between viral clade and disease severity phenotype. Future work that can leverage clinical outcome data with both viral and human genomic diversity is needed to monitor the pandemic.

13 February 2023 in bioRxiv
Verified
Preprint
Open access
PDF file
YLYenson Lau
Yenson Lau
JGJahir M. Gutierrez
Jahir M. Gutierrez
MVMaksims Volkovs
Maksims Volkovs
SZSaba Zuberi
Saba Zuberi
Leishmanisis, a neglected tropical disease caused by protozoan parasites of the genus Leishmania , affects millions of individuals living in poverty across the world and is second to malaria in parasitic causes of death. Although current drugs for treating leishmaniasis exist, these are either highly toxic, ineffective, or expensive. For this reason, there is an urgent need to identify affordable, safer, and more effective treatments. Drug repurposing is a promising method for identifying existing molecules with the potential to treat leishmaniasis. Here, we present a deep learning model for drug repurposing based on hyperbolic graph neural networks. We leverage experimentally validated protein-drug interactions and molecular descriptors across three different parasites to train and validate our model. The final network model shows significant gains over the best baseline model, with an 11.6% increase in precision of the top scoring 0.5% protein-drug pairs. Finally, our model identified two experimental drugs that could target three L. major proteins involved in drug resistance and cell cycle regulation, which play an essential role in ensuring the parasite’s survival inside the host. Author summary: Leishmanisis is a deadly and neglected tropical disease. Current treatments are ineffective, highly toxic, and unaffordable for the majority of affected individuals who live in extreme poverty. To accelerate the discovery and development of novel treatments against this disease, we develop a model that proposes existing drugs with the potential to treat leishmaniasis. Our methodology is based on hyperbolic graph neural networks, a class of deep learning models that can incorporate protein-drug interaction information from similar but well-studied parasites, in addition to utilizing chemical and molecular features. Empirically, this additional information leads to improved predictions of drug interactions with L. major proteins. Overall, the protein-drug pairs predicted by our model suggests two existing drugs that could target essential pathways for growth and survival of Leishmania parasites, which could be exploited either as a booster to increase the therapeutic effect of an existing anti-leishmaniasis drug, or as a novel chemotherapeutic treatment against the disease.

16 May 2025 in bioRxiv
Verified
Preprint
Open access
PDF file
BKBhargav Kanuparthi
Bhargav Kanuparthi
SPSara E. Pour
Sara E. Pour
SFScott D. Findlay
Scott D. Findlay
OWOmar Wagih
Omar Wagih
JGJahir M. Gutierrez
Jahir M. Gutierrez
BFBrendan J. Frey
Brendan J. Frey
MicroRNAs and RNA binding proteins are crucial elements of post-transcriptional gene regulation, which governs the fate of mRNA molecules in the cell. However, the landscape of these regulatory interactions, particularly across different mammalian cell types, remains underexplored. We describe REPRESS, a deep learning model that predicts cell-type-specific microRNA binding and mRNA degradation directly from RNA sequence. REPRESS was trained on AGO2-CLIP, miR-eCLIP and Degradome-Seq data profiling millions of microRNA binding and mRNA degradation sites across multiple cell types in human and mouse. It reveals biology that other state-of-the-art methods did not, such as identifying repressive non-canonical miRNA target sites and decoding the regulatory effects of sequence context and miRNA binding site multiplicity. REPRESS outperforms other advanced methods and neural architectures on a comprehensive suite of seven orthogonal tasks, including identifying genetic variants that affect microRNA binding, predicting out-of-distribution data from massively parallel reporter assays, and predicting canonical and non-canonical miRNA mediated repression. To demonstrate the general utility of REPRESS, we show that it provides insights into novel biology and the design of RNA therapeutics. Code is available at : https://github.com/deepgenomics/repress